Drug discovery is shifting from static snapshots to moving pictures. Instead of inferring how medicines work from end results ...

Alcohol use is widespread and alcohol use disorder (AUD) causes substantial harm. AUD affects 29 million individuals and ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Muse Treatment Alcohol & Drug Rehab Los Angeles has published a new educational resource that explains how opioid receptors ...

Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...

Humans have bitter taste receptors not only in their mouths but in their lungs, too. Researchers have exploited these receptors’ innate ability to dilate the airways to create a potent new drug that ...

The FDA is weighing the regulatory fate of KarXT — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. If approved, the fixed-dose combination of xanomeline and ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...